Liste des références
- Anker S., Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med 2021; 385:1451-146 Learn More
- Booth G et al, Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update, Can J Diabetes. 2016;40(6):484-486. Learn More
- Cherney D, Udell J, Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility. Circulation. 2016; 134:1915-1917. Learn More
- Diabetes Canada, Clinical Practice Guidelines, April 2018, Volume 42, Supplement 1. Learn More
- Di Angelantonio E et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52-60. Learn More
- M Evans et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49:930-936. Learn More
- Gerstein HC et al, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-30. Learn More
- Harris SB et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Diabetes Res Clin Pract. 2005; 70(1):90-97. Learn More
- Heerspink HJL et al, Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD), N Engl J Med 2020; 383:1436-1446. Learn More
- Inzucchi SE et al, Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. Circulation 2018, 138:1904-1907. Learn More
- Lipscombe L et al, Pharmacologic Glycemic Management of Type 2 Diabetes in Adults:2020 Update. Can J Diabetes, 44 (2020), 575-591. Learn More
- Mc Murray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). NEJM. 2019; 381:1995-2008. Learn More
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM. 2016; 375:311-22. Learn More
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM. 2016;375:1834-44. Learn More
- Monami M et al. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab, 2013;15:938-53. Learn More
- Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS). NEJM. 2017; 377:644-657. Learn More
- Packer M et al, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med 2020; 383:1413-1424. Learn More
- Perkovic M et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). NEJM. 2019; 380:2295-2306. Learn More
- Scirica BM et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (SAVOR-TIMI 53). NEJM 2013, 369;14: 1317-1326. Learn More
- Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE-TIMI). NEJM 2019: 380:347-57. Learn More
- Zhang L, Tamilia M, Euglycemic diabetic ketoacidosis associated with the use of a sodium–glucose cotransporter-2 inhibitor. CMAJ June 25, 2018 190 (25) E766-E768. Learn More
- Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). NEJM. 2015; 373:2117-28. Learn More